Barcelona-based Biorce, a HealthTech startup that uses artificial intelligence to revolutionize clinical trials, revealed that it has closed a $52 million Series A financing to fund international expansion, employ staff, and speed up product development.
DST Global Partners has contributed fresh capital to the round, while Norrsken VC, YZR Capital, Mustard Seed Maze, and other current investors have increased their participation. Notable angel investors include Nik Storonsky, CEO of Revolut; Paulo Rosado, creator of OutSystems; Albert Nieto, founder of Seedtag; and Arthur Mensch, co-founder and CEO of Mistral AI.
The startup secured €8.5 million in seed capital during a 12-month period, which included a €3.5 million round in November 2024, a €5 million extension from Norrsken VC in the summer of 2025, and now the €43.8 million Series A round. The company has raised more than $60 million in capital overall with this round.
Pedro Coelho, CEO of Biorce, stated: “The round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money, and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner. The speed at which we have raised capital since our last round in July 2025 is a strong validation of our technology, our team, and the impact we can generate.”
Addressing the Clinical Trial Crisis:
The goal of Biorce’s 2024 founding was to improve the clinical trial sector. It seeks to reduce clinical trial costs by more than half and expedite the delivery of life-saving medications to patients.
As per Biorce clinical studies take almost 11 years and cost $6.2 billion to bring a medicine to market, and that 57% of them involve expensive protocol changes that cause additional delays of months. According to Biorce, who cites SNS Insider, the management of clinical trials is anticipated to cost $120 billion annually worldwide. According to the conventional paradigm, any protocol change usually results in a six-week average pause in patient recruiting and an additional €500,000 to €1 million in expenses, which adds up to billions of euros in industry spending annually.
According to the Spanish startup, one of the main issues is that many teams find it difficult to explain their design choices to regulatory bodies like the FDA and the EMA. In the end, this slows patient access to treatments because it frequently results in reviews, delays, and more revisions.
Aika: The AI Platform Cutting Clinical Trial Times by 50%:
As a remedy, Biorce created Aika, a native AI platform that speeds up the creation of new treatments by up to 50% by cutting down on protocol modifications and clinical trial preparation times.
The platform allows pharmaceutical companies, biotech businesses, and CROs to design better studies more quickly without sacrificing scientific rigor or patient safety. It is based on a proprietary data foundation of around one million clinical trials. It asserts that by streamlining protocol creation, location selection, and feasibility evaluation, their AI platform seeks to improve operational efficiency, expedite timelines, and reduce complexity.
According to Biorce, “Aika is currently being used in a variety of therapeutic fields, such as neurology, oncology, and rare disorders. Biorce can leverage the impact of AI across a variety of clinical programs thanks to Aika’s therapy-agnostic methodology. Most AI solutions ask you to trust algorithms you can’t explain. We constructed the reverse. Complete paperwork is included with every Aika recommendation, which you can present to any regulatory body. Our “human-in-the-loop” strategy guarantees that the expert maintains command.”
What’s Next?
Biorce will be able to support international expansion, especially into the United States, thanks to the new funding. The business is getting ready to open an R&D and development center in Austin, Texas.
Plans to grow the team to about 250 workers by the end of 2026, with an emphasis on growing the engineering and commercial teams, will also be supported by the money. Additionally, it accelerates the development of new products. Additionally, Biorce stated that it concluded the previous year with income that was around 200% higher than its goal.
The team will concentrate on strengthening Aika’s protocol intelligence skills and launching additional modules, like contract management and negotiating tools, in the first quarter of 2026. In order to facilitate operational planning and budget discussion, more functions will be added. Biorce is finalizing a transfer to larger headquarters in Barcelona to accommodate its next phase of expansion.
Tove Larsson, General Partner at Norrsken VC, Board Member, said: “The platform is already seeing strong global demand, proving it can materially reduce timelines and costs for pharma and, more importantly, bring new treatments to patients faster than previously possible. That’s why we’re excited to double down on our investment. Their expansion into the U.S. is a natural next step and further cements the company’s trajectory toward becoming a category-defining force in clinical research.”
